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middle temporal gyrus. Perceptual distortion was correlated with different
regional CBF changes in the low- and high-dose groups.
Conclusions: Here, we provide evidence for the sensitivity of ASL to the
effects of ketamine and the strength of subjective experience, suggesting
plausible neural mechanisms for ketamine-induced anhedonia and cognitive
disorganisation.
57 Keywords separated
by ' - '
Glutamate receptor - NMDA Receptor - Neuroimaging - Cerebral blood flow
58 Foot note
information
   
   
U
N
C
O
R
R
EC
TE
D
PR
O
O
F
1
2
3 ORIGINAL INVESTIGATION
4 Phenomenologically distinct psychotomimetic effects of ketamine
5 are associated with cerebral blood flow changes in functionally
6 relevant cerebral foci: a continuous arterial spin labelling study
7 T. A. Pollak1 & S. De Simoni2 & B. Barimani3 & F. O. Zelaya4 & J. M. Stone4 & M. A. Mehta4
8
9 Received: 28 May 2015 /Accepted: 7 September 2015
10 # Springer-Verlag Berlin Heidelberg 2015
11 Abstract
12 Rationale The N-methyl-D-aspartate (NMDA) receptor an-
13 tagonist ketamine provides a pragmatic approach to address
14 the link between glutamate-mediated changes in brain func-
15 tion and psychosis-like experiences. Most studies using PET
16 or BOLD fMRI have assessed these symptoms broadly, which
17 may limit inference about specific mechanisms.
18 Objectives The objective of this study is to identify the cere-
19 bral blood flow (CBF) correlates of ketamine-induced psycho-
20 pathology, focusing on individual psychotomimetic symptom
21 dimensions, which may have separable neurobiological
22 substrates.
23 Methods We measured validated psychotomimetic symptom
24 factors following intravenous ketamine administration in 23
25 healthy male volunteers (10 given a lower dose and 13 a
26 higher dose) and correlated ketamine-induced changes in
27 symptoms with regional changes in CBF, measured non-
28 invasively using arterial spin labelling (ASL).
29 Results The main effect of ketamine paralleled previous stud-
30 ies, with increases in CBF in anterior and subgenual cingulate
31 cortex and decreases in superior and medial temporal cortex.
32Subjective effects were greater in the high-dose group. For
33this group, ketamine-induced anhedonia inversely related to
34orbi tofrontal cortex CBF changes and cognit ive
35disorganisation was positively correlated with CBF changes
36in posterior thalamus and the left inferior and middle temporal
37gyrus. Perceptual distortion was correlated with different re-
38gional CBF changes in the low- and high-dose groups.
39Conclusions Here, we provide evidence for the sensitivity of
40ASL to the effects of ketamine and the strength of subjective
41experience, suggesting plausible neural mechanisms for
42ketamine-induced anhedonia and cognitive disorganisation.
43Keywords Glutamate receptor . NMDAReceptor .
44Neuroimaging . Cerebral blood flow
45Introduction Q1
46Ketamine is an uncompetitive N-methyl-D-aspartate
47(NMDA) receptor antagonist that can exacerbate symptoms
48in patients with schizophrenia (Lahti et al. 1995) and in
49healthy volunteers produces positive, negative and cognitive
50symptoms that are thought to resemble those observed in
51schizophrenia (Krystal et al. 1994). While not producing a
52phenocopy of the disorder, the ketamine model provides a
53pragmatic approach to address how glutamate-mediated
54changes in brain function can cause psychotomimetic symp-
55toms (Corlett et al. 2011).
56Brain imaging studies produced amixture of findings when
57examining relationships between brain activity and the sub-
58jective effects of ketamine. Stone et al. used single photon
59emission tomography (SPET) to show that binding of keta-
60mine to NMDA receptors in middle inferior frontal cortex (as
61measured by displacement of the radiolabelled marker
62[(123)I]CNS-1261) was correlated with negative symptoms
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63 as measured by the brief psychiatric rating scale—BPRS
64 (Overall and Gorham 1962; Stone et al. 2008). Deakin et al.
65 used the clinician-administered dissociative symptoms
66 scale—CADSS (Bremner et al. 1998)—and BPRS to measure
67 the effects of ketamine. Functional magnetic resonance imag-
68 ing (fMRI) using the blood oxygen level-dependent phenom-
69 enon (BOLD) revealed signal reductions in medial OFC/
70 subgenual cingulate correlated with scores of dissociative
71 and psychotic symptomatology (using CADSS and BPRS)
72 and BOLD signal reductions in temporal pole also correlated
73 with dissociative symptomatology. Activations were correlat-
74 ed with CADSS and BPRS scores in the posterior cingulate
75 and with BPRS scores in frontal pole and parahippocampal
76 gyrus (Deakin et al. 2008). These findings differed from
77 Holcomb and colleagues who used H2O
15 PET and found a
78 correlation between BPRS scores and increased anterior cin-
79 gulate CBF following ketamine in a whole-brain analysis in
80 healthy volunteers (Holcomb et al. 2001). A similar correla-
81 tion between BPRS scores and anterior cingulate CBF follow-
82 ing ketamine was found in a subsequent ROI analysis in pa-
83 tients with schizophrenia (Holcomb et al. 2005).
84 These studies have all examined correlations with scales
85 measuring subjective effects in a relatively broad sense, each
86 scale combining a number of separable psychotomimetic
87 symptoms (e.g., perceptual abnormalities and delusional
88 thinking). The aim of the present study was to measure vali-
89 dated psychotomimetic symptom factors (De Simoni et al.
90 2013; Mason et al. 2008) following low-dose ketamine ad-
91 ministration in healthy volunteers and correlate changes in
92 individual symptom factors with changes in regional cerebral
93 blood flow (rCBF), measured non-invasively using arterial
94 spin labelling (ASL). The use of symptom factors may pro-
95 vide more accurate delineation of regional correlates of keta-
96 mine effects. The use of ASL allowed the assessment of brain
97 activity over a number of minutes of steady-state ketamine
98 administration, uncontaminated by the rapid changes in brain
99 activity observed using BOLD during a bolus administration
100 (De Simoni et al. 2013) and independent of sources of low
101 frequency noise (Aguirre et al. 2002).
102 ASL is a contrast-free MRI method that is directly sensitive
103 to regional CBF, in a manner analogous to H2O
15 positron
104 emission tomography (PET), but without requiring exposure
105 of the subjects to ionizing radiation. ASL allows the determi-
106 nation of absolute quantitative changes in a single physiolog-
107 ical parameter, elicited by the drug. In contrast, BOLD is
108 sensitive to both regional CBF and the regional rate of cerebral
109 oxygen metabolism (CMRO2). Thus, ASL is suitable for di-
110 rectly comparing the state during which ketamine is continu-
111 ously infused to achieve a steady plasma level, with the pre-
112 infusion ketamine state. The utility of ASL for this study
113 stems from the direct link between neuronal activity and re-
114 gional microcirculation (also known as ‘neurovascular cou-
115 pling’ (Attwell et al. 2010)); and has been confirmed by the
116results of recent investigations in which it was successfully
117employed to study the acute effects of various psychoactive
118compounds, including alcohol (Tolentino et al. 2011), psilo-
119cybin (Carhart-Harris et al. 2012), cocaine (Luo et al. 2009),
120cannabis (van Hell et al. 2011), propofol (Griffin et al. 2010),
121methylphenidate, atomoxetine (Marquand et al. 2012), fenta-
122nyl (Zelaya et al. 2012), aripiprazole and haloperidol (Handley
123et al. 2013).
124All studies investigating the effect of sub-anaesthetic keta-
125mine doses on CBF in humans to date have used H2O
15 PET:
126these have demonstrated increases in CBF in thalamic regions
127and in prefrontal, orbitofrontal and cingulate cortices in both
128healthy volunteers and schizophrenic patients (Holcomb et al.
1292005; Holcomb et al. 2001; Lahti et al. 1995; Langsjo et al.
1302003; Rowland et al. 2010). The only study to measure
131ketamine-induced CBF changes using ASL was performed
132in rodents, and the authors assessed CBF changes in the stri-
133atum only (Bruns et al. 2009).
134Given recent studies that have suggested a role for the
135anterior cingulate in mediating the psychotomimetic effects
136of ketamine (Holcomb et al. 2005; Stone et al. 2012), we
137chose also to take a ROI approach to see whether changes in
138any psychotomimetic symptoms correlated with changes in
139CBF within this region. Based on previous CBF studies
140(Holcomb et al. 2005; Holcomb et al. 2001), it was specifical-
141ly predicted that CBF changes in the anterior cingulate cortex
142would correlate with ‘positive symptom’ dimensions. We also
143predicted that previously observed negative correlations with
144OFC activity (Deakin et al. 2008) would be replicated and that
145these would relate to negative symptom scores such as anhe-
146donia, which are robustly induced by ketamine in healthy
147volunteers (Mason et al. 2008; Stone et al. 2008).
148Methods
149The data from this study were collected as part of two separate
150experiments with a low-dose and a high-dose ketamine ad-
151ministration protocol (De Simoni et al. 2013; Stone et al.
1522012; Stone et al. 2013). Healthy male volunteers were re-
153cruited by advertisement. Tenvolunteers (mean age 25.5 years,
154SD=6.5) were recruited to the low-dose ketamine group and
15513 volunteers to the high-dose ketamine group (mean age
15627.0 years, SD=6.9).
157Exclusion criteria included positive urine drug screen for
158drugs of abuse, the consumption of more than five cups of
159coffee (or equivalent) per day, smoking more than five ciga-
160rettes per day, taking prescription drugs and any history of
161mental illness or serious medical condition that in the opinion
162of the study doctors, prevented their participation in the study.
163Fulfillment of inclusion and exclusion criteria was assessed by
164a psychiatrist who completed a full psychiatric, neurological
165and medical examination of each participant (including
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166 electrocardiogram and urine drug screen). Written informed
167 consent was provided by all participants prior to their inclu-
168 sion in the study, which was approved by theWandsworth and
169 East London Research Ethics Committees.
170 Four patients in the high-dose ketamine group had already
171 taken part as volunteers in the low-dose ketamine group. At
172 least a year had elapsed since participation in the low-dose
173 ketamine group.
174 The study had an open-label design. Subjects completed
175 the psychotomimetic states inventory (PSI; 48 items
176 consisting of six subscales—delusional thinking, perceptual
177 distortion, cognitive disorganisation, anhedonia, mania and
178 paranoia (Mason et al. 2008)) before entering the scanner.
179 Following ketamine administration and the end of the scan,
180 subjects completed the PSI again, answering the items with
181 reference to the peak intensity of ketamine effects during the
182 scan. We used the PSI as it has been developed for use in
183 healthy volunteers, has excellent test–retest reliability and
184 has sensitivity to low-dose effects of ketamine (De Simoni
185 et al. 2013).
186 Imaging was performed using a 3.0T HDx MRI scanner
187 (GE Medical Systems, Milwaukee, WI, USA). All subjects
188 initially underwent a high-resolution T2-weighted structural
189 scan.
190 The ASL acquisition protocol differed slightly between the
191 low-dose and high-dose groups. This was due to modifica-
192 tions of the protocol to improve data quality between the ear-
193 lier (low-dose) and later (high-dose) studies.
194 Low-dose ASL acquisition
195 A whole brain, CBF map was obtained using a pseudo-
196 continuous flow-driven adiabatic inversion labelling scheme
197 during a 6-min ASL scan (labelling time 1.5 s, post-labelling
198 delay 15 s, TE/TR=32.256/5,500 ms, flip angle (FA)=90°).
199 Image data was acquired using a multi-shot, segmented 3D
200 stack of spirals (eight arms) with a resultant spatial resolution
201 of 2×2×3mm. Three control-label pairs were used to derive a
202 perfusion weighted difference image. A proton density image
203 was acquired in 48 s using the same acquisition parameters in
204 order to compute the CBFmap in standard physiological units
205 (ml blood/100 g tissue/min). Total acquisition time for each
206 ASL scan was 5:30 min.
207 High-dose ASL acquisition
208 ASL acquistion for the high-dose study used the same acqui-
209 sition parameters as the low-dose study except that in the high-
210 dose study the 3D volume of the image data was collected
211 axially instead of coronally and used additional saturation
212 bands.
213All subjects then underwent an intravenous ketamine infu-
214sion, which was dynamically modelled using a laptop com-
215puter running Stanpump software, driving a Graseby 3400
216syringe-driver. Infusion parameters used were based on the
217pharmacodynamics used by the Clements 250 model
218(Absalom et al. 2007). For the 10 subjects in the low-dose
219ketamine group, a target plasma level of 50–75 ng/mL was
220specified (in practice this approximated a rapid bolus of an
221average of 0.12 mg/kg over 20 s followed by a slow infusion
222of 0.31 mg/kg/h). For the 13 subjects in the high-dose keta-
223mine group, a target plasma level of 150 ng/mL was specified
224(in practice this approximated a rapid bolus of 0.26 mg/kg
225over 20 s followed by a slow infusion of 0.42 mg/kg/h).
226For both low- and high-dose ketamine groups, the ASL
227acquisitions were repeated at 10 min after the start of the
228ketamine infusion.
229In order to warp the CBF maps into a standard (MNI)
230space, individual T2-weighted images were used. Initially,
231T2-weighted images were skull stripped using the FSL Brain
232Extraction Tool (BET). The remaining steps were performed
233using SPM8 (www.fil.ion.ucl.ac.uk/spm). Raw CBF maps for
234each subject (pre- and post-ketamine) were co-registered with
235their corresponding stripped T2-weighted image and the same
236skull stripping was applied to the CBF maps. The stripped co-
237registered CBF images were then normalised to MNI space
238using the subject’s original anatomical T2-weighted image as
239a source and a skull-stripped T2-weighted template image
240(slice thickness 2 mm). These images were then smoothed
241using a 10-mm FWHM Gaussian kernel.
242Pre-ketamine CBF maps were subtracted from their
243corresponding post-ketamine CBF maps resulting in
244maps of ketamine-related change in CBF (Stewart
245et al. 2015).
246For each subject, pre-ketamine scores were subtracted from
247post-ketamine scores for each of the PSI subscales, to obtain a
248value for the change in scores for each subscale. SPSS was
249used to identify outliers in subjective response to ketamine by
250applying the ‘outlier’ function to the total scaled PSI scores for
251each participant. This was repeated separately for the high-
252dose and the low-dose ketamine groups. Data points identified
253as outliers represented those with values greater than 1.5 times
254the interquartile range from the upper quartile value. Imaging
255data were analysed using SPM8. To assess the main effects of
256ketamine on CBF, paired t test analyses were performed using
257the pre- and post-ketamine CBF maps. An absolute threshold
258of 14 ml/100 mg/min was applied to remove non-
259physiologically plausible CBF values from the analysis and
260most of deep white matter tissue where ASL measurements
261are unreliable due to the long arterial blood transit times. This
262produced a binary mask that was used in the subsequent re-
263gression analysis. Global CBF was calculated as the average
264signal across all analysed voxels and the analysis was
265corrected for global CBF.
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266 Separate whole-brain multiple regression analyses were
267 carried out for the low-dose and high-dose ketamine groups
268 using change in CBF as the dependent variable and the change
269 scores for each PSI subscale as the independent variables,
270 correcting for global CBF as above. For this analysis, in order
271 to minimise the inclusion of physiologically implausible (ei-
272 ther spatially or in terms of CBF value) voxels, we used an
273 explicit grey matter mask that had been multiplied with the
274 thresholded (at 14 ml/100 mg/min) binary mask from the t test
275 analysis (to remove voxels with no data). For statistical infer-
276 ence, we used cluster corrected statistics, selecting only clus-
277 ters which survived significance after family-wise error cor-
278 rection for multiple comparison based on cluster extent
279 (p<0.05); using a cluster forming threshold of p<0.01 at the
280 voxel level (as used in our previous studies:Mikita et al. 2015;
281 Zelaya et al. 2012). We also confirmed that the results were
282 unchanged using correction for non-stationarity of the data.
283 For the ROI analysis, we used an anterior cingulate volume
284 from the wfupickatlas toolbox (Maldjian et al. 2003). For
285 statistical inference within the ROI, we used family-wise error
286 corrected statistics at the voxel level.
287 Results
288 One subject in the high-dose ketamine group was identified as
289 an outlier, having the highest rated subjective effects. This
290 subject was excluded from the analyses.
291 In the low-dose group ketamine administration led to a
292 significant (paired t test; [mean(SD); p value]) increase from
293 baseline in subjective ratings on perceptual distortion
294 [0 .38(0.40) ; t (9) = 2.99; p = 0.015] and cogni t ive
295 disorganisation [0.20(0.19); t(9)=3.35; p<0.01]. There was
296 no significant increase for delusional thinking [0.03(0.05);
297 t(9)=1.50; p=0.168], anhedonia [0.11(0.22); t(9)=1.63; p=
298 0.137], mania [0.00(0.22); t(9)=0.00; p=0.999 ] or paranoia
299 [0.00(0.10); t(9)=0.00; p=1.0].
300 In the high-dose group, ketamine administration led to a
301 significant (paired t test; [mean difference(SD); p value]) in-
302 crease from baseline in subjective ratings on delusional think-
303 ing [0.27(0.41); t(11)=2.30; p=0.042], perceptual distortion
304 [0.68(0.44); t(11)=5.32; p<0.01], cognitive disorganisation
305 [0.60(0.57); t(11)=3.67; p<0.01], anhedonia [0.39(0.33);
306 t(11)=4.00; p<0.01] and mania [0.40(0.30); t(11)=4.56;
307 p<0.01]. There was no significant increase for Paranoia
308 [0.05(0.10); t(11)=1.82; p=0.096].
309 Ketamine-induced increases in subjective ratings were sig-
310 nificantly greater in the high-dose group versus the low-dose
311 group (independent samples t test; [scaled mean score in low-
312 dose group (standard deviation) vs scaled mean score in high-
313 dose group (standard deviation); p value] for cognitive
314 disorganisation [0.20(0.19) vs 0.60(0.57); t(20)=2.13; p=
315 0.046], anhedonia [0.11(0.22) vs 0.38(0.33); t(20)=2.18; p=
3160.042] and mania [0.00(0.22) vs 0.39(0.30) t(20)=3.42;
317p<0.01]. Changes in subjective ratings were not significantly
318different between dosages for delusional thinking [0.03(0.05)
319vs 0.27(0.41); t(11.4)=2.06; p=0.075], perceptual distortion
320[0.38(0.40) vs 0.68(0.44); t(20)=1.65; p=0.115] and paranoia
321[0.00(0.10) vs 0.05(0.09); t(20)=1.21; p=0.24]. See Fig. 1.
322We used paired t tests to assess the main effect of ketamine
323on CBF. Ketamine-induced increases in CBF were observed
324in the low-dose group in the right anterior cingulate (p<0.01;
325Table 1; Fig. 2a) and right ventromedial prefrontal cortex
326(p=0.01; Table 1; Fig. 2a). In the high-dose group,
327ketamine-induced CBF increases were more restricted,
328reaching significance in the right subgenual cingulate
329(p<0.01; Table 1; Fig. 2a). Ketamine-induced CBF decreases
330were observed in the low-dose group in the left retrosubicular
331hippocampal area (p<0.01; Table 2; Fig. 2a). In the high-dose
332group CBF decreases were observed in the right superior tem-
333poral cortex (p<0.01; Table 1; Fig. 2a Q3and 3).
334We found a negative correlation between CBF changes and
335changes in anhedonia scores for the high-dose ketamine group
336in the right orbitofrontal cortex extending into the right middle
337prefrontal gyrus (p<0.01; Table 2; Fig. 2b), such that greater
338ketamine-induced anhedonia was associated with increasingly
339negative CBF changes. There was a positive correlation be-
340tween changes in CBF and changes in cognit ive
341disorganisation scores for the high-dose ketamine group in
342the left posterior thalamus (p<0.01; Table 2; Fig. 2b) extend-
343ing into the left lingual gyrus as well as in the left inferior and
344middle temporal gyrus (p<0.01; Table 2; Fig. 2b).
345Correlations between CBF and changes in paranoia scores
346were not examined because of insufficient variance in para-
347noia scores in both the low- and high-dose ketamine groups
348(in general paranoia scores deviated only minimally from
Fig. 1 PSI subscale changes in low-dose and high-dose ketamine groups.
Note that data pertaining to the low-dose ketamine group overlap with
those previously reported by De Simoni et al. (2013)
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349 baseline under the influence of ketamine—see previous sec-
350 tion and Fig. 1). Changes in perceptual distortion scores were
351 correlated with different brain regions in the low- and high-
352 dose ketamine groups. In the low-dose group, there was a
353 significant negative correlation with CBF in right somatosen-
354 sory association cortex (p<0.01; Table 2). These correlations
355 were not observed in the high-dose ketamine group; instead in
356 this group a positive correlation between changes in CBF and
357 changes in perceptual distortion scores was observed in the
358 left medial thalamus (p=0.02; Table 2).
359 The ROI analysis did not reveal any significant correlations
360 between anterior cingulate CBF and changes in any of the PSI
361 subscales.
362Discussion
363In this study, we used ASL to examine the relationships be-
364tween different components of the subjective effects of keta-
365mine infusion and rCBF. We found meaningful correlations
366that provide support for the future role of ASL in analysing the
367brain basis of subjective effects of ketamine and other
368psychoactive medications. We interpret these changes in
369CBF as reflecting proximate effects of ketamine-induced
370changes in neuronal activity on glucose and oxygen
371metabolism. This is evidenced by studies which indi-
372cate, using subanaesthetic doses in humans and anaes-
373thetic doses in rats, that ketamine does not appear to
t1:1 Table 1 brain regions demonstrating CBF changes with ketamine
t1:2 Dose Anatomical region pFWE cluster level Cluster size T value Z score MNI coordinates (x, y z)
t1:3 CBF increases
t1:4 Low Right anterior cingulate 0.000 3,235 8.61 4.21 20 50 0
t1:5 Low Right ventromedial prefrontal cortex 0.011 1,578 5.08 3.30 12 18 −24
t1:6 High Right subgenual cingulate cortex 0.000 9,524 8.43 4.48 8 12 −14
t1:7 CBF decreases
t1:8 Low Left retrosubicular hippocampus 0.000 4,358 8.37 4.16 −32 −12 22
t1:9 High Right superior temporal cortex 0.000 4,692 10.66 4.92 64 −26 8
Fig. 2 a Changes in CBF with
ketamine in the low- and high-
dose groups overlaid on a high-
resolution T1-weighted image
from MRIcron. b regions
showing significant correlations
with PSI subscales overlaid on a
high-resolution T1-weighted
image fromMRIcron. The MNI Z
axis is shown at the top. The
colour bars show the t statistic
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375 Langsjo et al. 2003; Langsjo et al. 2004).
376 The dosing protocol was designed such that ASL images
377 were acquired when ketamine levels were at a steady state.
378 Thus, this study differs significantly from previous BOLD
379 studies where the effects of ketamine were captured in the
380period of infusion, including delivery of a bolus. In line with
381previous CBF studies of the effects of ketamine (Holcomb
382et al. 2001; Lahti et al. 1995; Rowland et al. 2010), we found
383a main effect of ketamine on CBF in anterior and subgenual
384areas of the cingulate cortex. Other effects were observed
385outside of this area, including decreases in CBF, although
t2:1 Table 2 Brain regions demonstrating correlations between CBF changes and changes in PSI subscale scores
t2:2 PSI subscale Dose Anatomical region pFWE
cluster
level
Cluster size T value Z score MNI
coordinates
(x, y, z)
t2:3 Cognitive disorganisation High Left inferior/middle temporal gyrus 0.000 5,054 7.85 4.21 −66 −36 −10
t2:4 Cognitive disorganisation High Left posterior thalamus
(extending into left lingual gyrus)
0.002 4,167 7.34 4.09 −14 −32 0
t2:5 Perceptual distortion High Left medial thalamus 0.015 2,683 9.85 4.61 −12 −16 14
t2:6 Perceptual distortion
(inverse correlation)
Low Right somatosensory association cortex 0.016 1,573 8.34 3.98 10 −42 66
t2:7 Anhedonia
(inverse correlation)
High Right inferior prefrontal gyrus, orbitofrontal
cortex (extending into middle prefrontal gyrus)
0.000 5,105 12.58 5.02 36 36 −18
Fig. 3 Changes in peak voxel activation with PSI subscale score. a Anhedonia—high dose; b Cognitive disorganisation—low dose; c Cognitive
disorganisation—high dose; d Perceptual distortion—high dose
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386 the areas of decrease were different in the high-dose and low-
387 dose groups, i.e. significant CBF decreases in the left
388 retrosubicular hippocampal area in the low-dose ketamine
389 group and in the right superior temporal cortex in the high-
390 dose ketamine group. This could reflect a dose-related differ-
391 ence in the ketamine response, although previous FDG-PET
392 studies have not seen similar changes. The goal of this study
393 was not to characterise the dose–response relationships of ke-
394 tamine and CBF and it was not optimised for direct compar-
395 isons between doses; instead, we focussed on the relationship
396 of those effects with the subjective measures acquired at
397 steady state.
398 Most of the significant correlations occurred in the high-
399 dose ketamine group. This is perhaps unsurprising given that
400 subjects in the high-dose group experienced significantly
401 greater subjective effects in most domains and that the
402 post-ketamine scores were more clustered in the lower
403 dose group. Because the low- and high-dose groups
404 were not a single cohort, we were unable to combine
405 them in the same correlational analysis to provide a
406 broader view of the dose response relationships.
407 Previous work has shown a dose–response effect for
408 the BOLD (De Simoni et al. 2013) and CBF (H2O
15
409 PET; (Langsjo et al. 2003)) response to ketamine and,
410 with the relatively small numbers in the study, correla-
411 tions were more likely to emerge when both subjective
412 effects and CBF were more pronounced.
413 Unlike earlier studies, we did not include the CADSS as a
414 measure of drug-induced dissociative experiences in this
415 study because we previously demonstrated its poor reliability
416 for the subjective effects of low-dose ketamine compared to
417 the PSI (De Simoni et al. 2013). Using the PSI, we have
418 extended the findings of Deakin et al. (2008), showing that
419 orbitofrontal cortex activity is inversely related to the subjec-
420 tive effects of ketamine. Here we have extended that finding
421 by showing that decreased CBF in the OFC, more specifically,
422 is inversely related to ketamine-induced anhedonia.
423 Although we identified a more lateral part of OFC than
424 Deakin and colleagues, the OFC is part of a network of re-
425 gions involved in reward and value processing (Kringelbach
426 2005). This network also includes the insula, amygdala and
427 ventral striatum, with the ventromedial PFC involved in sec-
428 ondary, domain independent processing of rewards and later-
429 al, posterior parts of OFC associated more strongly with pri-
430 mary reward processing (Sescousse et al. 2013; Sescousse
431 et al. 2010).
432 The ketamine-induced increase in anhedonia in this study
433 is similar to that observed with previous use of the PSI with
434 ketamine (Mason et al. 2008), but stands in apparent contrast
435 to its emerging use in treatment-resistant depression, in which
436 it has been demonstrated to exert a rapid and sometimes pro-
437 found anti-anhedonic effect (Lally et al. 2015). Given the use
438 of ketamine as an antidepressant, therefore, one might expect
439it to reduce anhedonia in our subjects. The PSI was not de-
440signed to assess depressive symptomatology in patient groups
441however and it is not clear that the acute, transient anhedonia
442experienced by subjects in this study has either phenomeno-
443logical or neurobiological overlap with the chronic state ex-
444perienced by patients with depression. Further, patients with
445depression have high baseline levels of anhedonia and there-
446fore may show a differential response to acute ketamine ad-
447ministration compared to healthy subjects.
448For the higher ketamine dose, the cognitive disorganisation
449factor was positively correlated with CBF changes in left in-
450ferior and middle temporal gyrus as well as the posterior thal-
451amus. Inspection of the items comprising this subscale (e.g.,
452‘Your mind jumps a lot from one thing to another’; ‘Your
453speech is difficult to understand because your words are all
454mixed up’) suggest that what is being tapped is something
455close to psychotic ‘thought disorder’, a term that refers to
456abnormalities of internal thought and to their manifestation
457through abnormalities of speech production. The left inferior
458and middle temporal gyri contain regions essential for the
459processing and production of coherent speech and abnormal-
460ities of activation in this area, asmeasured byBOLD response,
461have been linked to formal thought disorder in patients with
462schizophrenia (Kircher et al. 2001). The pulvinar of the thal-
463amus, located within the other significant cluster, projects to
464several cortical areas, including prefrontal and limbic regions,
465as well as having rich projections to and from sensory cortices;
466disruption to this region can produce deficits in verbal and
467non-verbal processing (Ojemann et al. 1968) and its function
468is abnormal in schizophrenia (Andrews et al. 2006).
469Perceptual distortion was correlated with decreases in CBF
470in somatosensory association cortex under low-dose keta-
471mine, but not at the higher dose. This subscale of the PSI
472includes items that relate to somatosensory distortions (e.g.,
473‘You feel as though your head, limbs or body have somehow
474changed’), suggesting that these decreases in CBF might un-
475derlie perceptual distortion in the somatosensory modality.
476Studies of hallucinations in psychotic patients and experimen-
477tally induced hallucinations in healthy controls have similarly
478implicated somatosensory areas (Blankenburg et al. 2006;
479Nemoto et al. 2010; Shergill et al. 2001). It is unclear why
480these correlations were not seen in the high-dose ketamine
481group, which instead saw a positive correlation with changes
482in CBF in the left medial thalamus. This ASL study was not
483suitable for a dose response connectivity analysis although
484thalamo-cortical connectivity is a candidate marker for dose
485response effects related to perceptual distortions based on our
486findings. The thalamus is an integral part of perceptual net-
487works in both visual and somatosensory modalities and might
488be expected to undergo CBF changes under conditions of
489intense perceptual distortion with high-dose ketamine.
490Dawson et al. reported that ketamine administration in rats
491led to marked changes in the connectivity of multiple thalamic
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492 nuclei with the prefrontal cortex (Dawson et al. 2013). It is
493 interesting to note that chronic ketamine users have lower
494 levels of thalamic N-acetyl-aspartate suggesting a potential
495 effect of long-term ketamine use on neural integrity in this
496 brain region (Stone et al. 2013).
497 We were unable to replicate the association between CBF
498 in anterior cingulate cortex and the overall subjective effects
499 of ketamine that had been noted previously (Holcomb et al.
500 2005; Holcomb et al. 2001), although a main effect of keta-
501 mine at both doses was seen in this region. Notably these
502 earlier studies, which used H2O
15 PET, found a correlation
503 with the psychosis subscale of the BPRS, the items of which
504 relate to a number of phenomenologically separable psychotic
505 symptoms. In fact the heterogeneity of items within this sub-
506 scale means that it brings together elements which in the PSI
507 are tapped by separable subscales. For example, items relating
508 to symptoms of cognitive disorganisation and perceptual dis-
509 tortion, which in the PSI feature in separate subscales, would
510 be subsumed within the psychosis subscale of the BPRS,
511 which was used in the PET CBF studies. Although we did
512 not find a correlation with subjective effects of ketamine in our
513 ROI analysis, whole-brain analysis revealed correlations be-
514 tween regional changes in CBF and variables that may have
515 more clinical and phenomenological meaning.
516 Limitations
517 The number of participants in the present study was relatively
518 low, but to date there have been no investigations into the
519 effects of ketamine on quantitative blood flow measurements.
520 This study demonstrates the feasibility and utility of such
521 techniques. This method differs from the related BOLD tech-
522 niques (De Simoni et al. 2013; Deakin et al. 2008) because
523 these assess the change in BOLD signal, incorporating the
524 rapid changes at the time of infusion. Here, we use a quanti-
525 tative technique to allow assessment of steady-state effects a
526 number of minutes later.
527 Because quantitative blood flowmeasurements are a devel-
528 oping technique in MRI, optimisations have emerged over
529 recent years and attempts to produce high-quality data in each
530 study have occurred at the expense of standardisation. The
531 fact that we used slightly different acquisition protocols for
532 the low and high-dose groups limited formal comparison of
533 the ketamine effect, although the focus here was the relation-
534 ship with subjective ratings, which would be relatively unaf-
535 fected as both methods have similar signal-to-noise
536 characteristics.
537 Here, we have assumed a linear model for the effects of
538 ketamine, whereas the effects may be non-linear. This is sug-
539 gested by the perceptual distortion relationships differing in
540 regions with dose. Investigations of multiple doses, preferably
541within subjects would be required to understand these rela-
542tionships. To date, such a study has not been conducted.
543Conclusion
544We have demonstrated the utility of ASL as a non-invasive
545tool in the investigation of the physiological correlates of the
546subjective effects of ketamine, the first such study to use this
547modality to investigate psychoactive drug effects in this way.
548Meaningful correlations between changes in subjective expe-
549rience and in CBF were identified. In particular, the correla-
550tions between anhedonia and orbitofrontal cortex CBF and
551that between perceptual abnormalities and areas subserving
552sensory processing point towards a plausible mechanism for
553striking aspects of the ketamine experience. This study is also
554the first to use ASL to replicate the central role, already
555established in other imaging modalities, of the anterior cingu-
556late cortex in mediating the main effect of ketamine.
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